Epigenomics AG successfully completes capital increase

Epigenomics AG / Key word(s): Capital Increase/Corporate Action
Epigenomics AG successfully completes capital increase

07-Nov-2019 / 23:36 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

NOT FOR PUBLICATION, DISTRIBUTION OR TRANSMISSION TO OR WITHIN THE UNITED STATES OF AMERICA, CANADA, JAPAN AND AUSTRALIA.

Epigenomics AG successfully completes capital increase

Berlin, 7 November 2019 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) has placed the new shares from the capital increase resolved on October 17, 2019 in an amount of EUR 7,506,152.00. Accordingly, the Company's share capital will be increased from currently EUR 36,021,540.00 by EUR 7,506,152.00 to EUR 43,527,692.00 by 7,506,152 new registered shares of the Company against cash contributions.

The shares from the private placement were allocated to multiple investors, including, in particular, institutional investors from the U.S.A. and Germany.

The gross proceeds from the capital increase amount to approximately EUR 8.3 million.

The capital increase needs to be registered in the commercial register, which the Executive Board will apply for shortly. The inclusion of the new shares under the Company's existing listing (ISIN DE000A11QW50) is currently expected to take place at or around November 13, 2019.
 

Contact:
Company
Epigenomics AG
Genest Street 5
10829 BerlinTel
+49 (0) 30 24345 0
Fax +49 (0) 30 24345 555
E-mail: ir@epigenomics.com
 

Investor Relations
IR.on AG
Frederic Hilke, Fabian Kirchmann
Phone +49 221 9140 970
E-mail: ir@epigenomics.com

Important Notice

This publication does not constitute or form part of, and should not be construed as an offer or an invitation to sell, or issue or the solicitation of any offer to buy or subscribe for, any securities. The shares will be solely offered on the basis of the published subscription offer and the prospectus approved by the German Federal Financial Supervisory Authority (BaFin - Bundesanstalt für Finanzdienstleistungsaufsicht). The prospectus was published on the Company's website at www.epigenomics.com after approval by BaFin on October 18, 2019. The subscription offer was published on October 21, 2019.

This publication does, in particular, not constitute an offer to sell or a solicitation of an offer to purchase any securities in the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or the laws of any state within the U.S., and may not be offered or sold in the United States or to or for the account or benefit of U.S. persons, except that the offered shares may be offered or sold to qualified institutional buyers in reliance on certain exemptions from the registration requirements of the Securities Act and applicable state securities laws. This publication and the information contained herein may not be distributed or sent into the United States, or in any other jurisdiction in which offers or sales of the securities described herein would be prohibited by applicable laws, and should not be distributed to United States persons or by way of publications with a general circulation in the United States. No public offering of the shares is being made in the United States. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan. The securities referred to herein have not been and will not be registered under the applicable securities laws of Australia, Canada or Japan.

Forward-Looking Statements

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any expected results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

07-Nov-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de